As of 2025-07-02, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -16.44 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 12.5x | 10.4x |
| Forward P/E multiples | 11.6x - 20.2x | 15.9x |
| Fair Price | (169.31) - (182.65) | (191.92) |
| Upside | -144561.0% - -155945.5% | -163851.4% |
| Date | EV/EBITDA |
| 2025-06-25 | 0.18 |
| 2025-06-24 | 0.18 |
| 2025-06-23 | 0.18 |
| 2025-06-20 | 0.18 |
| 2025-06-18 | 0.18 |
| 2025-06-17 | 0.18 |
| 2025-06-16 | 0.18 |
| 2025-06-13 | 0.18 |
| 2025-06-12 | 0.18 |
| 2025-06-11 | 0.18 |
| 2025-06-10 | 0.18 |
| 2025-06-09 | 0.18 |
| 2025-06-06 | 0.18 |
| 2025-06-05 | 0.18 |
| 2025-06-04 | 0.18 |
| 2025-06-03 | 0.18 |
| 2025-06-02 | 0.18 |
| 2025-05-30 | 0.18 |
| 2025-05-29 | 0.18 |
| 2025-05-28 | 0.18 |
| 2025-05-27 | 0.18 |
| 2025-05-23 | 0.18 |
| 2025-05-22 | 0.18 |
| 2025-05-21 | 0.18 |
| 2025-05-20 | 0.18 |
| 2025-05-19 | 0.18 |
| 2025-05-16 | 0.18 |
| 2025-05-15 | 0.18 |
| 2025-05-14 | 0.18 |
| 2025-05-13 | 0.18 |
| 2025-05-12 | 0.18 |
| 2025-05-09 | 0.18 |
| 2025-05-08 | 0.18 |
| 2025-05-07 | 0.18 |
| 2025-05-06 | 0.18 |
| 2025-05-05 | 0.18 |
| 2025-05-02 | 0.18 |
| 2025-05-01 | 0.18 |
| 2025-04-30 | 0.18 |
| 2025-04-29 | 0.18 |
| 2025-04-28 | 0.18 |
| 2025-04-25 | 0.18 |
| 2025-04-24 | 0.18 |
| 2025-04-23 | 0.18 |
| 2025-04-22 | 0.18 |
| 2025-04-21 | 0.18 |
| 2025-04-17 | 0.18 |
| 2025-04-16 | 0.18 |
| 2025-04-15 | 0.18 |
| 2025-04-14 | 0.18 |